Human plasma derived antithrombin — Competitive Intelligence Brief

Human plasma derived antithrombin (Human plasma derived antithrombin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticoagulant; serine protease inhibitor. Area: Cardiovascular; Hematology.

phase 3 Anticoagulant; serine protease inhibitor Thrombin (Factor IIa), Factor Xa, and other activated coagulation factors Cardiovascular; Hematology Small molecule

Target snapshot

Human plasma derived antithrombin (Human plasma derived antithrombin) — Octapharma. Antithrombin is a natural anticoagulant protein that inhibits blood clotting factors to prevent thrombosis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Human plasma derived antithrombin TARGET	Human plasma derived antithrombin	Octapharma	phase 3	Anticoagulant; serine protease inhibitor	Thrombin (Factor IIa), Factor Xa, and other activated coagulation factors
C1 inhibitor (human) [C1 INH]	C1 inhibitor (human) [C1 INH]	Shire	marketed	Complement inhibitor / Serine protease inhibitor	C1s protease / Classical complement pathway
C1 Esterase Inhibitor (Human)	C1 Esterase Inhibitor (Human)	Shire	marketed	Serine protease inhibitor; complement regulator	C1 esterase inhibitor (C1-INH); Factor XIIa; plasma kallikrein
Nafamostat Mesilate	Nafamostat Mesilate	Chong Kun Dang Pharmaceutical	marketed	Serine protease inhibitor	Serine proteases (thrombin, factor Xa, kallikrein, trypsin)
C1 esterase inhibitor [human] liquid	C1 esterase inhibitor [human] liquid	Shire	phase 3	Serine protease inhibitor; plasma-derived protein replacement	C1 esterase inhibitor (C1-INH); Factor XIIa, Factor XIa, Kallikrein
Low-volume C1-esterase inhibitor	Low-volume C1-esterase inhibitor	CSL Behring	phase 3	Serine protease inhibitor / Complement regulator	C1-esterase inhibitor (C1-INH protein)
Higher-volume C1-esterase inhibitor	Higher-volume C1-esterase inhibitor	CSL Behring	phase 3	Serine protease inhibitor / Complement regulator	C1-esterase (C1s), Factor XIIa, Plasma kallikrein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticoagulant; serine protease inhibitor class)

1. Octapharma · 1 drug in this class